Partial agonists and schizophrenia: Theoretical developments for the development of mental health nursing

Journal of Psychiatric and Mental Health Nursing

Volumn 16, Issue 5, 2009, Pages 409-415

  Jones, M ^a   White, J ^b   Gray, R ^c  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

Mental health nursing; Partial agonists; Quality of life

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; HUMAN; NURSING; NURSING RESEARCH; PSYCHIATRIC NURSING; PSYCHOLOGY; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL BEHAVIOR;

ANTIPSYCHOTIC AGENTS; HUMANS; NURSING RESEARCH; PSYCHIATRIC NURSING; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 65549099198     PISSN: 13510126     EISSN: 13652850     Source Type: Journal    
DOI: 10.1111/j.1365-2850.2009.01373.x     Document Type: Article

References (43)

1. Brooker C. (2001) A decade of evidenced based training for work with people with serious mental health problems: progress in the development of psychosocial interventions. Journal of Mental Health 10, 17 31. (Pubitemid 32269879)
2. Brooker C. Brabban A. (2004) Measured Success: A Scoping Review of Evaluated Psychosocial Interventions Training for Work with People with Serious Mental Health Problems. NIHME/Trent WDC Sheffield.
3. Brown S., Inskip H. Barraclough B. (2000) Causes of the excess mortality of schizophrenia. British Journal of Psychiatry 177, 212 217.
4. Cook A.J. Razzano L. (2000) Vocational rehabilitation for persons with schizophrenia and implications for practice. Schizophrenia Bulletin 26, 87 103. (Pubitemid 30317694)
5. Department of Health (2001) Final Report by the Workforce Action Team-Mental Health National Service Framework, Workforce Planning, Education and Training. HSMO, London.
6. Department of Health (2005) Improving Mental Health Services by Extending the Role of Nurses in Prescribing and Supplying Medication, Good Practice Guide. HSMO, London.
7. Department of Health (2006a) From Values to Action: The Chief Nursing Officer's Review of Mental Health Nursing. HSMO, London.
8. Department of Health (2006b) Mental Health Bill Summary Guide. HMSO, London.
9. Drachman D.A. (1977) Memory and cognitive functioning in man; does the cholinergic system have a specific role? Neurology 27, 783 790. (Pubitemid 8171670)
10. Fadden G. (1997) Implementation of family interventions in routine clinical practice following staff programs: a major cause for concern. Journal of Mental Health 6, 599 612. (Pubitemid 28062681)
11. Faulkner G., Cohn T., Remington G., et al. (2007) Body mass index, waist circumference and quality of life in individuals with schizophrenia. Schizophrenia Reserve 90, 1 3, 174 178. (Pubitemid 46188514)
12. Fenton W.S., McGlashan T.H. Victor B.J. (1997) Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. American Journal of Psychiatry 154, 199 204. (Pubitemid 27053725)
13. Gur R.E., Kohler C.G., Ragland J.D., et al. (2006) Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophrenia Bulletin 32, 279 287.
14. Halbreich U., Kinon B.J., Gilmore J.A., et al. (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28, 53 67. (Pubitemid 36015661)
15. Hannssens L., L'Italien G., McQuade R., et al. (2006) Evaluation of quality of life in community-treated schizophrenic patients: a naturalistic open-label study comparing aripiprazole to standard of care (schizophrenia trial of aripiprazole: star study). European Psychiatry 21 (Suppl. 1 S1 S250.
16. Heinrichs D.W., Hanlon T.E. Carpenter W.T. Jr. (1984) The Quality of Life Scale: an instrument for rating the schizophrenia syndrome. Schizophrenia Bulletin 10, 388 398.
17. Heinrichs R.W. Zakzanis K.K. (1998) Neurocognitive deficit in schizophrenia a quantitative review of the evidence. Neuropsychology 12, 426 445. (Pubitemid 28323862)
18. Hofer A., Kemmler G., Eder U., et al. (2004) Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication and side effects. Journal of Clinical Psychiatry 65, 932 939.
19. Jones M. Gray R. (2008) Time to wake up and smell the coffee: antipsychotic medication and schizophrenia. Journal of Psychiatric and Mental Health Nursing 15, 344 348.
20. Jones M. Jones A. (2008) The effect of antipsychotic medication on metabolic syndrome. Nursing Standard 22, 43 48.
21. Jones P.B., Barnes T.R., Davies L., et al. (2006) Randomised controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia (CUtLASS 1). Archives of General Psychiatry 63, 1079 1087. (Pubitemid 44498387)
22. Kikuchi T., Tottori, K. Uwahodo, Y. (1995) A new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonist activity. Journal of Pharmacological Experimential Therapy 274, 329 336.
23. Knegtering H., Lambers P.A., Prakken G., et al. (2000) Serum prolactin levels and sexual dysfunctions in antipsychotics medications, such as risperidone: a review. Acta Neuropsychiatry 12, 19 26. (Pubitemid 30148708)
24. Lieberman J.A., Stroup T.S., McEvoy M.D., et al. (2005) Effects of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 353, 1209 1223. (Pubitemid 41345943)
25. Maslach C., Jackson S.E. Leiter M.P. (1996) Maslach Burnout Inventory Mannual. Consuting Psychologist Press, Palto Alto, CA.
26. Melmed S. (1995) The Pituitary. Blackwell Science, Cambridge, MA.
27. Miles C.P. (1977) Conditions predisposing to suicide: a review. Journal of Nervous and Mental Disease 164, 231 246. (Pubitemid 8092555)
28. Mittal D., Davis C.E., Depp C., et al. (2006) Correlates of healthy related quality of well-being in older patients with schizophrenia. Journal of Nervous and Mental Disease 194, 335 340. (Pubitemid 43841198)
29. National Institute of Clinical Excellence (2002a) Clinical Guidelines I, Schizophrenia Core Interests in the Treatment and Management of Schizophrenia in Primary and Secondary Care. HMSO, London.
30. National Institute of Clinical Excellence (2002b) Guidance on the use of newer (atypical) antipsychotics for the treatment of schizophrenia. Health Technology Appraisal, No 43, London.
31. Olfson M., Uttaro T., Carson W.H., et al. (2005) Male sexual dysfunction and quality of life in schizophrenia. Journal of Clinical Psychiatry 66, 331 338. (Pubitemid 40476756)
32. Perenyi A. Forlano R. (2005) Suicide in schizophrenia. Neuropsychopharmacology 19, 408 413.
33. Pigott T.E., Carson W.H. Saha A.R. (2003) Aripiprazole for the prevention of relapse for the prevention of relapse in astabilised patients with chronic schizophrenia: a placebo controlled 26 week study. Journal of Clinical Psychiatry 64, 1048 1056. (Pubitemid 37158250)
34. Puschner B., Born A., Giebler A., et al. (2006) Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study. Journal of Nervous and Mental Disease 194, 746 752. (Pubitemid 44581101)
35. Stahl S.M. (2001) Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press, Cambridge.
36. Strakowski S.M., Johnson J.L., Delbello M.P., et al. (2005) Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. Schizophrenia Research 78, 161 169. (Pubitemid 41254020)
37. Strejilevich S., Palatnik A., Avila R., et al. (2005) Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Research 133, 277 280. (Pubitemid 40312161)
38. Sullivan G., Bienroth M., Jones M., et al. (2007) Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Current Medical Research and Opinion 23, 1733 1744. (Pubitemid 47122182)
39. Tardieu S., Micallef J., Gentile S., et al. (2003) Weight gain profiles of new anti-psychotics: public health consequences. Obesity Reviews 4, 129 138. (Pubitemid 36950575)
40. Taylor D., Paton C. Kerwin R. (2007) The Maudsley Prescribing Guidelines, 9th edn. Informa Healthcare, London.
41. Turkington D., Dudley R., Warman D.M., et al. (2004) Cognitive- behavioural therapy for schizophrenia: a review. Journal of Psychiatric Practice 10, 5 16.
42. White J., Gray R. Jones M. (2007) Aripiprazole: a new option for people with schizophrenia. Mental Health Practice 10, 28 30.
43. Young I.S. (2005) Lipids for psychiatrists: an overview. Journal of Psychopharmacology 19 (Suppl. 6 66 75. (Pubitemid 44567860)